Proficio Capital Partners LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Proficio Capital Partners LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 148,040 shares of the medical research company's stock, valued at approximately $29,091,000. Proficio Capital Partners LLC owned approximately 0.08% of IQVIA as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. Private Trust Co. NA grew its holdings in shares of IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its position in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Howard Capital Management Inc. boosted its position in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the last quarter. Huntington National Bank boosted its position in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company's stock valued at $192,000 after purchasing an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on IQV shares. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Truist Financial reaffirmed a "buy" rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. cut their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective for the company. Finally, Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $251.22.

Insider Buying and Selling

In other news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

IQV stock traded down $4.13 during midday trading on Monday, reaching $184.67. 1,421,318 shares of the stock were exchanged, compared to its average volume of 1,444,588. The stock has a market capitalization of $32.52 billion, a PE ratio of 24.62, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $184.06 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a fifty day moving average price of $198.84 and a 200 day moving average price of $214.25.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.